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Abstract models have been developed to describe dissolution of Pu/Am/Cm after internal contamination by inhalation or
wound, chelation of actinides by diethylene triamine penta acetic acid (DTPA) in different retention compartments and
excretion of actinide–DTPA complexes. After coupling these models with those currently used for dose calculation, the mod-
elling approach was assessed by fitting human data available in IDEAS database. Good fits were obtained for most studied
cases, but further experimental studies are needed to validate some modelling hypotheses as well as the range of parameter
values. From these first results, radioprotection tools are being developed: MAnagement of DOse Reduction after DTPA
therapy.
INTRODUCTION
Since several decades, diethylene triamine penta
acetic acid (DTPA) has been used to enhance
excretion of Pu/Am/Cm after accidental contami-
nation in human(1). DTPA treatment has to be done
promptly after the accident in order to decrease sys-
temic retention associated with the presence of
soluble actinides. Depending on chemical forms of
the actinides and contamination levels, delayed treat-
ments could also be performed which significantly
increase faecal and urinary excretion of the actinides.
The first modelling approach has considered that
only extracellular actinides are chelated by DTPA
and then fastly excreted in urine(2). To explain the
delay urinary excretion of actinide–DTPA, about 5 %
of the chelates are supposed to be retained in an uni-
dentified extracellular compartment with half-time
of 1 week. This modelling approach can be applied
to single treatments, but in the case of repeated,
one’s actinide decorporation is underestimated(3).
Thus, other sources of chelated actinides have to be
considered which involved systemic intracellular
compartments(4, 5) and the site of contamination(5).
Recently, identification of the main sources of Pu/
Am chelated by DTPA as well as improved knowl-
edge of decorporation processes were obtained from
targeted animal experiments. Thus, the structure of
new models to describe decorporation of Pu/Am by
DTPA have been proposed which take into account
actinide speciation and their localisation within
different compartments(6 – 9). At this time, such
complex structures are difficult to be combined with
current models used to describe actinide biokinetics
in human for dose calculation(10 – 13).
Simplification of modelling is needed to provide,
in a next future, tools suitable for a radioprotection
purpose. The aim of this study was to test a first
version of a new radioprotection tool: MAnagement
of DOse Reduction after DTPA therapy (MADOR)




Figure 1 shows the dissolution model used which is
a combination of those reported after inhalation(10)
and wound(13).
Four compound behaviours have been considered
corresponding to fractions of deposited material fr,
fcol (col as colloids), fs and fss. Dissolution rates of
these fractions gradually decrease from sr, scol, ss and
sss. A fraction fb of the dissolved actinides is retained
in extra- and intracellular pulmonary compartments
before reaching the blood stream at a rate sb. This
bound fraction was only considered in alveolar inter-
stitium (ai1, ai2 and ai3) which contains most of the
lung actinides for the first years after contamination.
Chelation and excretion models
From recent experimental data(6 – 9), it was assumed
that once formed actinide–DTPA are stable in the
different retention compartments. Ninety per cent of
extracellular complexes are promptly excreted in
urine and 3 % in faeces. The remainder (7 %) is
retained in cells of soft tissues and return to blood
with half-time (lcell) of about 1 week (Figure 2).
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Two chelation processes have been taken into
account: early chelation which involves retention
compartments at the time of treatment and delayed
chelation which involves free intracellular DTPA
chelating new actinide deposits.
For simplification, early chelation occurs only in
three sites: liver 0 or 1 depending on the systemic
model applied, blood and interstitial fluids (ST0),
and at the site of contamination. An efficacy of che-
lation (ef) is assigned to each of these compartments
which corresponds to the fraction of chelated acti-
nides. The rate of transport to blood and to bile (l),
in the case of the liver, varies according to the extra-
or intracellular location of the complexes (Figure 2).
Delayed chelation only occurs in the liver and at
the contamination site in fb. Depending on the
galenic form and DTPA dosage, a free chelating
agent concentration is assigned to these compart-
ments. This concentration decreases at a rate lDTPA.
Above a threshold concentration, chelation efficacy
is assigned a constant value, and below, it decreases
linearly with an adjustable slope. Two retention
compartments of Act–DTPA are then considered
with transfer to blood or bile at different rates
(Figure 3).
Other models and human data
These three models are coupled to the model of par-
ticle transport(10), systemic models of ICRP(11), or in
the case of Pu, to the model recently proposed by
Leggett et al.(12) and gastrointestinal model of
ICRP30(14).
The most relevant cases available on the web in
IDEAS internal contamination database(15) have
been used for a first validation of our simplified
modelling approach. A reference number is assigned
to each contamination case which corresponds to
that provided in the database.
RESULTS AND DISCUSSION
Fit examples
More than 12 inhalation or wound cases involving
Pu, Am or Cm could be well fitted using different
parameter values. Figures 4 and 5 show the fit
examples of well-documented human cases after
inhalation exposure to aerosols containing Am or
Pu.
Case 17 provides measurements of excretion and
retention. Chelation of Am is clearly pointed out in
the liver which is associated with an increase in
faecal excretion of the actinide similar to that
measured in urine.
Cases 249 and 250 have been chosen to quantify
delayed urinary excretion of Pu and the influence of
pulmonary administration of DTPA compared with
i.v. In fact, the increased urinary excretion of Pu
on the first day after treatment corresponds only to
10 % of the cumulative urinary excretion associated
with 1 DTPA administration. Half of the total
urinary excretion of Pu–DTPA is achieved within
Figure 1. Dissolution model applied to inhalation and
wound. Black boxes correspond to compartments in which
chelation of actinides by DTPA could occur.
Figure 2. Model applied to describe early chelation.
Different fractions of chelated actinides are considered
depending on their route of excretion (liver: blood or bile
fbloodþfbile¼1) or their location (site: intra- or extracellular
fintraþfextra¼1).
Figure 3. Model applied to describe delayed chelation.
lDTPA corresponds to the rate of transport of free DTPA
from cells to blood, whereas two fractions of Act–DTPA
are considered ( f0þf1¼1) which leave the cells at different
rates, l0 and l1, respectively. Once transferred, behaviour
of Act-DTPA is the same as described in Figure 1.
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1 week, whereas 75 % within 2 weeks. Pulmonary
administration of DTPA increases delayed excretion
which is in agreement with a chelation of newly dis-
solved Pu. Good fit of this delayed excretion could
be obtained by increasing the amount of free chelat-
ing agent retained in the lungs.
In these different cases, similar DTPA amounts
were administered (30 mmol kg21). The fits shown
in the figures were obtained by using similar ef
values for both early chelation (effb¼efliver¼0.8 and
efblood¼0.1) and delayed chelation (ef¼0.8 in fb and
liver when free DTPA concentration was larger than
the threshold).
Although good fits are obtained for most cases
studied (more than 12), this does not mean that our
modelling approach is validated. In fact, it is a pure
fitting assessment and new experimental data are
needed, especially as a concern range of some par-
ameter values ( fb, sb, efliver, efblood . . .), so that realis-
tic parameters could be applied to human.
Moreover, intracellular chelation in soft tissues such
as red bone marrow and gonads has to be con-
sidered for dosimetric benefits due to their high WT
values.
Simulations to improve dose reduction by DTPA
The calculation of dose reduction associated with
DTPA therapy has been done for each case studied.
A simulation tool has been developed to assess dose
reduction depending on the treatment schedule.
Recently, an early treatment schedule has been pro-
posed which corresponds to daily i.v. of Ca–DTPA
(0.5 g) for 3 d, three times a week for 3 weeks and
Figure 5. Urinary excretion of Pu after inhalation of the
same radiocontaminant. A: case 249, B: case 250 and C: fit
after DTPA inhalation taking into account an increased
retention of free chelating agent in the lungs.
Figure 4. One of the best fit obtained for case 17 (Am type
M/S). Each bar on the x-axis corresponds to a DTPA i.v.
Figure 6. Simulations of effective dose reduction obtained
after different DTPA treatment schedules following a 650
Bq wound by type M or S 239Pu.
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once a week for 3 months(16). Figure 6 shows after
wound contamination the effective dose reduction
for type M or S 239Pu, associated with such a sche-
dule and the dose benefits if treatment is continued
for 5 or 50 y at different time intervals.
Long-term treatments can reduce doses by factors
from 3 to 6. However, repeated i.v. for several years
appear unrealistic but oral administration of DTPA
might be done(17). After wound, equivalent dose
delivered locally is not taken into account for effec-
tive dose calculation. This is not the case after inha-
lation and for type M, the maximal dose reduction
should be 92 %, whereas only 42 % for type
S. However, potential chelation of colloids as well
as alteration of alpha dose distribution within the
lungs due to DTPA administration could contribute
to health benefits not associated with a significant
dose reduction. The lung equivalent doses corre-
spond to average values and the presence of hot
spots appears to reduce the occurrence of lung
tumours compared with more homogeneous alpha
irradiation(18). Thus, chelation of actinides retained
as fb which are homogeneously distributed within
lung parenchyma(6) might reduce risk for lung
tumour induction, whereas particle aggregation
within fibrotic scars should decrease dose delivered
to target cells(18).
CONCLUSION AND PERSPECTIVES
This study shows that a simple modelling approach
could be applied for management of DTPA therapy
based on equivalent and effective dose reduction.
Three different versions of MADOR are being
developed:
† V1 is dedicated to physicians and radioprotec-
tion. It is a didactic tool corresponding to
improvement of the previous MEDOR
software(19, 20). Very fast access to calculation
results will be obtained by using simplified
models.
† V2 is an accurate calculation tool for an exper-
tise purpose.
† V3 is software taking into account actinide spe-
ciation and localisation in rodents. If improve-
ment of DTPA efficacy can be obtained, e.g.
using different galenic forms, this tool will be
transposed to human to obtain the best dosi-
metric estimates.
V1 and V2 should be fully validated by the end of
2012 using both human data and results of new tar-
geted animal experiments.
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